Healthpeak Properties, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Healthpeak Properties, Inc. stock analysis DOC overview
Somewhat Bullish +50

Healthpeak Properties Gains 22.7% Year to Date: Will the Trend Last?

📈 Healthpeak Properties (DOC) shares have gained 22.7% year-to-date, significantly outperforming the healthcare real estate industry's 12.7% gain.

🏥 The company is strategically focusing on lab, outpatient medical, and life plan assets in high-barrier markets to drive growth.

🔬 In Q1 2026, Healthpeak executed 141,000 square feet of lab leases with 92% tied to new leasing, raising total occupancy to 77.7%.

🏥 The outpatient medical segment achieved nearly 1.1 million square feet in leases and maintained 91% total occupancy with strong tenant retention.

👴 Janus Living, the senior housing platform, reported a 35% year-over-year revenue growth and 42% adjusted EBITDA expansion in Q1 2026.

💰 The company generated $267 million in proceeds from dispositions and recapitalizations to fund focused growth and enhance liquidity.

📉 Net debt-to-EBITDA stood at 5.4x at the end of Q1 2026, while cash and equivalents rose to $1.17 billion following the Janus Living IPO.

🏦 Healthpeak maintains strong credit ratings of Baa1 from Moody's and BBB+ from S&P Global as of May 4, 2026.

📉 Management is using structured transactions to maintain investment flexibility across different economic cycles.

⚠️ Risks include competition from other healthcare services players, rising construction costs, and a substantial debt burden.

🏆 DOC carries a Zacks Rank #3 (Hold), while competitors like American Tower (AMT) and Lamar Advertising (LAMR) hold higher Buy ratings.

📊 The article notes that anything related to earnings presented represents Funds From Operations (FFO), a key metric for REITs.

Bullish Signals
  • Shares of Healthpeak Properties (DOC) have gained 22.7% year-to-date, significantly outperforming the industry's upside of 12.7%.
  • The company executed 141,000 square feet of lab leases in Q1 2026, with 92% tied to new leasing and total lab occupancy rising to 77.7% from 77% at year-end 2025.
  • Outpatient medical segment achieved 5.4% cash re-leasing spreads on renewals, ended Q1 2026 at 91% total occupancy, and reported a larger pipeline under letter of intent (LOI).
  • Janus Living reported year-over-year revenue growth of 35% and adjusted EBITDA expansion of 42% for the first quarter of 2026.
  • Senior housing same-store cash net operating income (NOI) grew 13.8% year over year in Q1 2026, reflecting stronger operating performance.
  • Healthpeak generated $267 million in proceeds from recapitalizations, dispositions, and loan repayments in Q1 2026 to fund focused growth while maintaining investment flexibility.
  • Cash and cash equivalents rose to $1.17 billion from $467.5 million in the last quarter following Janus Living IPO proceeds.
  • The company maintained strong long-term credit ratings of Baa1 from Moody's and BBB+ from S&P Global as of May 4, 2026.
Risk Factors
  • Competition from other industry players in the healthcare services sector is explicitly identified as a key concern for Healthpeak.
  • The article states that substantial debt burden adds to the company's woes.
Full Analysis
Healthpeak Properties (DOC) shares have gained 22.7% year-to-date, outperforming the healthcare real estate industry's 12.7% gain. The company is strategically focusing on lab, outpatient medical, and life plan assets in high-barrier markets, supported by strong leasing momentum and rising occupancy. In the first quarter of 2026, Healthpeak executed 141,000 square feet of lab leases with 92% tied to new leasing, bringing total lab occupancy to 77.7%. The outpatient medical segment saw nearly 1.1 million square feet of leases executed in Q1 2026, achieving a 5.4% cash re-leasing spread and ending the quarter at 91% total occupancy. The company's senior housing platform, Janus Living, showed significant growth with same-store cash net operating income increasing 13.8% year over year in Q1 2026. Janus Living reported a 35% year-over-year revenue growth and a 42% adjusted EBITDA expansion for the quarter. Healthpeak is using dispositions and structured transactions to fund this focused growth, generating $267 million in proceeds from recapitalizations, dispositions, and loan repayments in Q1 2026. The company ended the quarter with net debt-to-EBITDA of 5.4x and increased cash and cash equivalents to $1.17 billion following Janus Living's IPO proceeds. To bolster liquidity, Healthpeak added a new $400 million unsecured delayed-draw term loan as of May 4, 2026, maintaining long-term credit ratings of Baa1 from Moody's and BBB+ from S&P Global. Management expects year-end 2026 lab occupancy to be higher than the 2025 level, driven by continued demand in core clusters like San Diego, San Francisco, and Boston. The company is repositioning its portfolio toward these high-barrier markets while maintaining investment flexibility across cycles.